Inclusion Body Myositis Market Research Report 2030 | Inclusion Body Myositis Market
What is Inclusion Body Myositis?
Inclusion body myositis (IBM) is an inflammatory and degenerative muscle disease that causes painless weakening of muscle. IBM gets worse slowly and is usually conflicted as treatment-resistant polymyositis, another inflammatory muscle disease that causes muscle weakness.
DelveInsight's launched new report named "Inclusion Body Myositis Market Report 2030” delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology also due to the inclusion body Myositis market trends within the 7MM.
Inclusion Body Myositis Sign and Symptoms
In Inclusion Body Myositis, the onset of muscle weakness usually is gradual, occurring over months or years. Falling and tripping usually are the primary noticeable symptoms.
People with Inclusion Body Myositis may have:
- Difficulty with gripping.
- Weakness of the finger and quadriceps muscles.
- Shrinking of the muscles of the forearms.
- Weakness of the lower limb muscles.
- Weakness of the esophageal muscles.
The Inclusion Body Myositis market report 2030 provides Inclusion Body Myositis treatment algorithms and therapies in the 7mm.
Got queries? Read more @ Inclusion Body Myositis Market Outlook
Inclusion Body Myositis Treatment Option
The disease isn't responsive to corticosteroids and immunosuppressive drugs – two drugs that sometimes treat inflammatory or autoimmune conditions. Some evidence suggests that intravenous immunoglobulin may help slightly during a little number of cases, but not beneficiary for long. Physical therapy could be helpful in keeping joints mobility. Other therapy, including treatments for the swallowing problems, is symptomatic and supportive.
Inclusion Body Myositis Epidemiology Insights
Degenerative mechanisms like protein accumulation and vacuolar transformation within the skeletal muscle distinguish inclusion body myositis (IBM) from other inflammatory myopathies. IBM is especially common in patients over the age of fifty years and inevitably results in progressive muscle weakness and atrophy.
Key Insights:
● A study, specified that recent work estimated the Inclusion Body Myositis prevalent population in northern Europe to 3.3/100 000.
● A study quoted that data from Japan indicated that the prevalence was 10 per million in 2003.
● According to a study the estimated incidence of IBM, adjusted for sex and age to the 2000 US Census population, was 7.9 cases per million inhabitants with a prevalence of 70 cases per million inhabitants.
The Inclusion Body Myositis Epidemiology section of the report also includes information on the diagnosed patient pool, trends, and assumptions used.
For each of the seven major countries, the Inclusion Body Myositis epidemiology section provides information on historical and present Inclusion Body Myositis patient pools, as well as predicted trends.
Request for sample pages of the report @ https://www.delveinsight.com/sample-request/inclusion-body-myositis-market
Inclusion Body Myositis Market Insights
The expected launch of Orphazyme shall fuel the growth of the market during the forecast period, i.e., 2021–2030. The market size shall grow during the forecast period due to the launch of upcoming therapies. The market size is expected to increase during the study period (2018-2030).
Key Insights:
● Before 2010, no International Classification of Diseases, Ninth Revision, Clinical Modification (ICD9CM) code existed for IBM, making estimates of the prevalence and health-care costs from US medical payment databases quite impossible.
● In 2018, the utilization of this code to estimate US healthcare costs for patients with IBM and Medicare coverage suggests annual costs of 35,000 US dollars per annum in more than the prices of matched controls and a prevalence of 84 per million in people >65 years aged.
● Overall, annual all-cause healthcare resource use was higher among sIBM patients. The differences were driven mainly by more all-cause office visits but sIBM patients also showed significantly higher rates of all-cause ER visits and hospitalizations.
According to DelveInsight, the Inclusion Body Myositis Market in 7MM is expected to change in the study period 2018-2030.
Inclusion Body Myositis Emerging Therapy Assessment
Key players involved in the development of therapies for the treatment of Inclusion Body Myositis patients are:
- Arimoclomol: Orphazyme
- ALZ-507: Alzehon
- Dalazatide: Kv1.3 Therapeutics
- And others.
Arimoclomol by Orphazyme
Orphazyme received a Fast Track designation from the FDA for the development of arimoclomol for the treatment of sporadic Inclusion Body Myositis (sIBM).
ALZ-507 by Alzehon
Alzehon is developing an anti-oligomer agent, ALZ-507 for the treatment of Inclusion Body Myositis and Dry AMD.
Dalazatide by Kv1.3 Therapeutics
Kv1.3 Therapeutics is evaluating Dalazatide for inclusion body myositis (IBM). It's a Kv1.3 inhibitor of Kv1.3 potassium channels for systemic disease.
The emerging therapy assessment segment of the Inclusion Body Myositis report encloses an in-depth analysis of Inclusion Body Myositis marketed drugs and late-stage pipeline drugs.
Visit our repository of reports @ DelveInsight Report Store
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Comments
Post a Comment